Col003 attenuates sepsis-associated coagulation dysfunction in mice in association with reduced platelet activation...

Area of Science:

• Immunology
• Hematology
• Pathophysiology

Background:

• Sepsis-induced coagulation dysfunction significantly increases mortality.
• Platelet activation, neutrophil activation, and neutrophil extracellular trap (NET) formation are key contributors to sepsis pathophysiology.
• Heat shock protein 47 (HSP47) is implicated in venous thromboembolism and platelet/neutrophil activation, but its role in sepsis-related coagulopathy is unclear.

Purpose of the Study:

• To investigate the role of HSP47 in sepsis-associated platelet activation, NET formation, and coagulation dysfunction.
• To evaluate the therapeutic potential of inhibiting HSP47-associated responses using Col003.

Main Methods:

• A murine model of sepsis was induced via cecal ligation and puncture (CLP).
• Mice were treated with Col003, an HSP47 inhibitor, and various parameters including platelet activation, NET formation, coagulation, and survival were assessed.
• In vitro experiments explored the involvement of the TLR2-MyD88 pathway in HSP47-mediated NET formation.

Main Results:

• CLP induced increased platelet HSP47 signaling, coagulation abnormalities, platelet activation, and NET formation, which were attenuated by Col003 treatment, improving survival.
• Early administration of Col003 (3 hours before CLP) demonstrated the most significant protective effects.
• In vitro studies confirmed that HSP47 promotes NET formation via the TLR2-MyD88 pathway.

Conclusions:

• HSP47-associated responses play a critical role in sepsis-induced coagulation dysfunction, linked to platelet activation and NET formation.
• Early intervention with Col003 targeting HSP47 pathways shows promise for treating sepsis-associated coagulopathy.
• Further research is needed to assess the efficacy of delayed Col003 administration after sepsis onset.